市場調査レポート

商品コード

1422069

医薬品原薬の世界市場：合成別、力価別、メーカー別、タイプ別、薬剤別、用途別、地域別、機会、予測、2017年～2031年

Active Pharmaceutical Ingredient Market Assessment, By Synthesis, By Potency, By Manufacturer, By Type, By Drug, By Usage, By Application, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 217 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の医薬品原薬の市場規模は、2023年に2,117億5,000万米ドルと評価され、2031年には3,693億米ドルに達すると予測されており、2024年から2031年の予測期間のCAGRは7.2%になると見込まれています。世界の医薬品原薬市場は、医薬品需要の増加、慢性疾患の罹患率の増加、バイオテクノロジーとバイオ医薬品の普及、ジェネリック医薬品市場の繁栄、人工知能のような技術の進歩といった要因の影響を受けています。

世界の医薬品原薬市場は、製薬セクターの基本的な柱として機能しており、世界の健康水準の向上と維持に不可欠な重要な医薬品の製剤化と製造に必要な必須成分を供給しています。ヘルスケアの情勢が絶え間なく進化する中、医薬品原薬（API）市場の重要性はますます顕著になっています。世界の医薬品原薬市場は、インドと中国を筆頭とするアジア太平洋地域が主に牽引しており、コスト面での優位性と高度な技能を持つ労働力の恩恵を受けています。これとは対照的に、北米と欧州は、製薬産業が盛んであることが主な理由で、依然として重要な原薬消費国です。

世界の医薬品原薬市場は、人口の高齢化とヘルスケアへのアクセス向上に努める新興市場によって大きく左右される医薬品需要の増加によって大きく影響を受けています。バイオテクノロジーとバイオ医薬品の利用は、主にその独創的で精密な治療用途のために、生物学的由来の原薬の需要を増大させています。ブロックバスター医薬品の特許切れにより、ジェネリック医薬品部門は引き続き活性化しており、費用対効果の高い生産を実現するためにAPIに大きく依存しています。一方、人工知能（AI）やその他の技術の進歩は、医薬品の研究開発・生産に変革をもたらし、APIの効率性と費用対効果を高め、世界の医薬品原薬市場の成長につながります。

当レポートでは、世界の医薬品原薬市場について調査し、市場の概要とともに、合成別、力価別、メーカー別、タイプ別、薬剤別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 3. Global Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 4. Global Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 5. Global Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 6. Global Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 7. Global Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 8. Global Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 9. Global Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 10. Global Active Pharmaceutical Ingredient Market Share (%), By Region, 2017-2031F
Figure 11. North America Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 12. North America Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 13. North America Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 14. North America Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 15. North America Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 16. North America Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 17. North America Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 18. North America Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 19. North America Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 20. North America Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
Figure 21. United States Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 22. United States Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 23. United States Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 24. United States Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 25. United States Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 26. United States Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 27. United States Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 28. United States Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 29. United States Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 30. Canada Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 31. Canada Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 32. Canada Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 33. Canada Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 34. Canada Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 35. Canada Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 36. Canada Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 37. Canada Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 38. Canada Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 39. Mexico Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 40. Mexico Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 41. Mexico Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 42. Mexico Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 43. Mexico Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 44. Mexico Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 45. Mexico Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 46. Mexico Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 47. Mexico Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 48. Europe Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 49. Europe Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 50. Europe Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 51. Europe Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 52. Europe Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 53. Europe Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 54. Europe Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 55. Europe Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 56. Europe Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 57. Europe Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
Figure 58. Germany Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 59. Germany Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 60. Germany Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 61. Germany Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 62. Germany Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 63. Germany Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 64. Germany Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 65. Germany Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 66. Germany Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 67. France Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 68. France Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 69. France Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 70. France Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 71. France Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 72. France Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 73. France Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 74. France Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 75. France Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 76. Italy Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 77. Italy Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 78. Italy Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 79. Italy Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 80. Italy Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 81. Italy Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 82. Italy Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 83. Italy Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 84. Italy Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 85. United Kingdom Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 86. United Kingdom Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 87. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 88. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 89. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 90. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 91. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 92. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 93. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 94. Russia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 95. Russia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 96. Russia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 97. Russia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 98. Russia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 99. Russia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 100. Russia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 101. Russia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 102. Russia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 103. Netherlands Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 104. Netherlands Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 105. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 106. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 107. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 108. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 109. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 110. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 111. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 112. Spain Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 113. Spain Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 114. Spain Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 115. Spain Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 116. Spain Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 117. Spain Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 118. Spain Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 119. Spain Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 120. Spain Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 121. Turkey Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 122. Turkey Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 123. Turkey Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 124. Turkey Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 125. Turkey Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 126. Turkey Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 127. Turkey Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 128. Turkey Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 129. Turkey Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 130. Poland Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 131. Poland Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 132. Poland Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 133. Poland Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 134. Poland Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 135. Poland Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 136. Poland Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 137. Poland Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 138. Poland Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 139. South America Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 140. South America Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 141. South America Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 142. South America Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 143. South America Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 144. South America Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 145. South America Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 146. South America Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 147. South America Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 148. South America Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
Figure 149. Brazil Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 150. Brazil Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 151. Brazil Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 152. Brazil Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 153. Brazil Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 154. Brazil Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 155. Brazil Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 156. Brazil Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 157. Brazil Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 158. Argentina Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 159. Argentina Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 160. Argentina Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 161. Argentina Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 162. Argentina Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 163. Argentina Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 164. Argentina Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 165. Argentina Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 166. Argentina Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 167. Asia-Pacific Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 168. Asia-Pacific Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 169. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 170. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 171. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 172. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 173. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 174. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Usage, In USD Billion, 2016-2030
Figure 175. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 176. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
Figure 177. India Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 178. India Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 179. India Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 180. India Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 181. India Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 182. India Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 183. India Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 184. India Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 185. India Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 186. China Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 187. China Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 188. China Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 189. China Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 190. China Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 191. China Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 192. China Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 193. China Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 194. China Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 195. Japan Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 196. Japan Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 197. Japan Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 198. Japan Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 199. Japan Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 200. Japan Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 201. Japan Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 202. Japan Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 203. Japan Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 204. Australia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 205. Australia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 206. Australia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 207. Australia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 208. Australia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 209. Australia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 210. Australia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 211. Australia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 212. Australia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 213. Vietnam Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 214. Vietnam Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 215. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 216. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 217. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 218. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 219. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 220. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 221. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 222. South Korea Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 223. South Korea Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 224. South Korea Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 225. South Korea Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 226. South Korea Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 227. South Korea Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 228. South Korea Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 229. South Korea Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 230. South Korea Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 231. Indonesia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 232. Indonesia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 233. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 234. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 235. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 236. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 237. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 238. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 239. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 240. Philippines Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 241. Philippines Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 242. Philippines Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 243. Philippines Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 244. Philippines Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 245. Philippines Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 246. Philippines Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 247. Philippines Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 248. Philippines Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 249. Middle East & Africa Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 250. Middle East & Africa Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 251. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 252. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 253. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 254. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 255. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 256. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 257. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 258. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
Figure 259. Saudi Arabia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 260. Saudi Arabia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 261. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 262. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 263. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 264. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 265. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 266. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 267. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 268. UAE Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 269. UAE Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 270. UAE Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 271. UAE Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 272. UAE Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 273. UAE Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 274. UAE Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 275. UAE Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 276. UAE Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 277. South Africa Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
Figure 278. South Africa Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
Figure 279. South Africa Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
Figure 280. South Africa Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
Figure 281. South Africa Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
Figure 282. South Africa Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
Figure 283. South Africa Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
Figure 284. South Africa Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
Figure 285. South Africa Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
Figure 286. By Synthesis Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 287. By Potency Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 288. By Manufacturer Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 289. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 290. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 291. By Usage Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 292. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 293. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10934

Global active pharmaceutical ingredient market size was valued at USD 211.75 billion in 2023, expected to reach USD 369.3 billion in 2031, with a CAGR of 7.2% for the forecast period between 2024 and 2031F. The global active pharmaceutical ingredient market is influenced by factors such as rising pharmaceutical demand, growing incidence of chronic illnesses, widespread adoption of biotechnology and biopharmaceuticals, thriving market for generic drugs, and advancements in technologies like artificial intelligence.

The global active pharmaceutical ingredient market functions as the fundamental pillar of the pharmaceutical sector, providing the essential components required for the formulation and manufacturing of crucial medicines, which are indispensable for enhancing and maintaining global health standards. With the healthcare landscape evolving continuously, the active pharmaceutical ingredient (API) market's significance grows more pronounced. The global active pharmaceutical ingredient market is predominantly led by Asia-Pacific, with India and China at the forefront, benefiting from cost advantages and a highly skilled workforce. In contrast, North America and Europe remain significant API consumers, largely due to their thriving pharmaceutical industries.

Global active pharmaceutical ingredient market is greatly influenced by rising demand for pharmaceuticals, largely driven by aging populations and emerging markets striving to improve healthcare accessibility. The utilization of biotechnology and biopharmaceuticals has amplified the request for biologically derived APIs, primarily due to their inventive and precise therapeutic applications. The expiration of patents for blockbuster drugs continues to energize the generic drug sector, which heavily depends on APIs to achieve cost-effective production. Meanwhile, artificial intelligence (AI) and other technological advancements are ushering in a transformation in drug research, development, and production, enhancing the efficiency and cost-effectiveness of APIs, leading to growth in the global active pharmaceutical ingredient market.

Increasing Global Demand for Pharmaceuticals

Shifting demographics, particularly the aging of populations across various regions, contribute significantly to the heightened need for healthcare interventions, consequently driving pharmaceutical demand upwards. Additionally, the rising prevalence of chronic diseases, often linked to shifts in lifestyle and urbanization, amplifies the requirement for medications aimed at managing and treating these health issues. With expanding economies and improved healthcare accessibility, more individuals can afford and access essential medications, thereby further stimulating the global pharmaceutical market.

Furthermore, the persistent pursuit of groundbreaking therapies and treatments, coupled with the rapid expansion of biotechnology and personalized medicine, sustains a continuous demand for pharmaceutical products. The demand encompasses traditional drugs and extends to biopharmaceuticals and novel therapeutic approaches, thus broadening the pharmaceutical market's scope. In essence, the mounting global demand for pharmaceuticals results from an intricate interplay among demographic, economic, and technological factors, with healthcare requirements standing as the central driver of the burgeoning trend.

Technological Progress is Propelling the Market Forward

Breakthroughs in cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML) are instigating a profound transformation in the production of active pharmaceutical ingredients (APIs). Within the global active pharmaceutical ingredient market, AI and ML systems are increasingly harnessed for their capacity to streamline processes, minimize errors, and augment operational efficiency. These innovations enable real-time monitoring and predictive analytics, thereby facilitating manufacturers in maintaining consistent quality and yield standards. By scrutinizing extensive datasets and recognizing underlying patterns, AI and ML algorithms contribute to developing more effective and precise production methodologies that indirectly boost the global active pharmaceutical ingredient market.

As an incidence of AI and ML's impact, a recent study, featured in a publication of May 2023 of Nature Communications, authored by MIT and Takeda researchers, introduced a groundbreaking approach that combines physics principles with machine learning to classify the irregular surfaces characterizing particles within mixtures. Employing a physics-enhanced autocorrelation-based estimator (PEACE), the technique can potentially revolutionize pharmaceutical manufacturing processes for tablets and powders. It promises heightened efficiency, precision, and a reduction in the occurrence of failed batches, thereby elevating the overall productivity and accuracy of pharmaceutical product manufacturing.

Government Initiatives

Governments worldwide are implementing a range of strategies to attain self-reliance in active pharmaceutical ingredient (API) production, boosting growth in the global active pharmaceutical ingredient market. The strategic endeavor stems from acknowledging the pivotal role APIs play in ensuring a steady supply of essential medications, particularly during global crises, like the COVID-19 pandemic. Governments are actively promoting the growth of domestic API manufacturing capabilities to reduce reliance on foreign sources, fortify national healthcare security, and mitigate potential vulnerabilities in the supply chain. These efforts often encompass investments in research and development, providing incentives for domestic production, streamlining regulatory procedures, and fostering collaboration between public and private sectors to bolster the resilience and capacity of domestic API production.

For instance, in March 2023, a minister of Canada unveiled a federal investment initiative to boost the country's capability to research and produce essential medications. The initiative, backed by over USD 80.5 million in federal funding and based in Edmonton, will empower emerging pharmaceutical companies to introduce new products to the market and cultivate talent in Alberta's life sciences sector. The Canadian Critical Drug Initiative is designed to augment Canada's manufacturing capacity and supply chain, thus reducing the nation's reliance on foreign sources for active pharmaceutical ingredients. Simultaneously, it supports the commercialization of crucial medicines, contributing to healthcare self-sufficiency.

High Demand for HPAPIs

The demand for High Potency Active Pharmaceutical Ingredients (HPAPIs) is substantial in the global active pharmaceutical ingredient market due to their pivotal role in pharmaceutical formulations. Approximately one-quarter of pharmaceutical drugs worldwide feature HPAPIs, recognized for their exceptional effectiveness. HPAPIs are compounds that demonstrate potent pharmacological activity at low concentrations, making them indispensable for addressing intricate health conditions like cancer and autoimmune disorders. Their precision and strength enable precise therapeutic targeting, reducing adverse effects while optimizing treatment outcomes.

Given their fundamental contribution to contemporary healthcare, the demand for HPAPIs remains robust, as researchers and pharmaceutical firms continuously explore their potential for innovating advanced and highly efficacious medicines. For instance, in July 2023, Evonik and Heraeus Precious Metals joined hands to broaden their respective portfolios of services pertaining to highly potent active pharmaceutical ingredients (HPAPIs). The collaboration harnesses unique HPAPI expertise of both firms to deliver a comprehensive solution, spanning from the early preclinical phases to full-scale commercial production. The integrated offering includes a seamless transition between small-scale and large-scale manufacturing processes, enabling a more efficient and versatile approach to HPAPI development and production.

Growing Demand for Therapeutic Enzymes

The global active pharmaceutical ingredient market is witnessing a notable increase in the demand for APIs that rely on enzymes. Enzymes are crucial in formulating pharmaceuticals by facilitating targeted drug delivery and improving therapeutic effectiveness. The upsurge in demand is driven by several factors, including the growing adoption of biotechnology in drug research, the emergence of precision medicine, and the pharmaceutical industry's increasing emphasis on sustainable and eco-friendly manufacturing practices. Enzyme-based APIs offer significant benefits like precise action, reduced side effects, and environmentally conscious production methods. Consequently, they have become an essential component in developing cutting-edge pharmaceuticals, effectively addressing both therapeutic requirements and sustainability objectives within the evolving pharmaceutical sector. For instance, in October 2022, Gingko Bioworks unveiled a partnership with Merck, with the goal of enhancing the production of active pharmaceutical ingredients. The initiative involves the genetic engineering of potentially four enzymes to serve as biocatalysts in Merck's API production endeavors.

Future Market Scenario

The global active pharmaceutical ingredient market's future is characterized by optimistic growth prospects driven by several key factors. To begin with, the pharmaceutical industry's dedication to innovation and substantial investments in research and development are poised to stimulate the demand for specialized APIs. The trend is particularly pertinent as pursuing precision medicine and targeted therapies gains traction, necessitating novel APIs with unique attributes.

Additionally, sustainability will be pivotal in shaping the API market's trajectory. The adoption of green chemistry practices and eco-friendly production methods aligns with global environmental initiatives and resonates with a growing number of environmentally conscious consumers and regulatory bodies. Furthermore, cultivating international collaborations and partnerships will provide access to diverse markets and resources, thereby augmenting the API market's growth potential. To summarize, the bright future of the API market hinges on innovation, sustainability, regulatory compliance, and robust supply chain strategies.

Key Players Landscape and Outlook

Prominent pharmaceutical firms are progressively joining forces to produce APIs. The cooperative initiative is geared towards boosting operational efficiency, cost reduction, and expediting the creation of vital drugs. These corporations can consolidate their capabilities, simplify manufacturing procedures, and secure a consistent API supply through the exchange of resources, research findings, and expertise.

Furthermore, such partnerships help them lessen the vulnerabilities linked to depending solely on one supplier, thus reinforcing their adaptability when confronted with unexpected difficulties. Ultimately, these collaborations play a crucial role in advancing the global active pharmaceutical ingredient market, ensuring the availability of essential medications, and improving patient access to life-saving treatments.

A recent example involved the cooperation of four companies in July 2022, to offer a dedicated service for the rapid development of mobile units for API production, known as the Production Intelligente de Principes Actifs (PIPAc) project. The initiative aims to streamline the complex and lengthy supply chains associated with API production. PIPAc encompasses synthesis, continuous flow chemistry, in-flow analysis, and leverages artificial intelligence (AI) to design efficient production units equipped with autonomous capabilities.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Active Pharmaceutical Ingredient Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Synthesis
- 4.2.1. Biotech
  - 4.2.1.1. Monoclonal Antibodies
  - 4.2.1.2. Hormones
  - 4.2.1.3. Cytokines
  - 4.2.1.4. Recombinant Proteins
  - 4.2.1.5. Therapeutic Enzymes
  - 4.2.1.6. Vaccines
  - 4.2.1.7. Blood Factors
- 4.2.2. Synthetic
4.3. By Potency
- 4.3.1. Traditional API
- 4.3.2. HPAPI
4.4. By Manufacturer
- 4.4.1. Captive APIs
- 4.4.2. Merchant APIs
4.5. By Type
- 4.5.1. Generic APIs
- 4.5.2. Innovative APIs
4.6. By Drugs
- 4.6.1. Prescription Drugs
- 4.6.2. Over-the-counter Drugs
4.7. By Usage
- 4.7.1. Clinical
- 4.7.2. Research
4.8. By Application
- 4.8.1. Cardiovascular Diseases
- 4.8.2. Oncology
- 4.8.3. CNS and Neurology
- 4.8.4. Orthopedic
- 4.8.5. Endocrinology
- 4.8.6. Pulmonology
- 4.8.7. Gastroenterology
- 4.8.8. Nephrology
- 4.8.9. Ophthalmology
- 4.8.10. Communicable Diseases
- 4.8.11. Diabetes
- 4.8.12. Pain Management
- 4.8.13. Others
4.9. By Region
- 4.9.1. North America
- 4.9.2. Europe
- 4.9.3. South America
- 4.9.4. Asia-Pacific
- 4.9.5. Middle East and Africa
4.10. By Company Market Share (%), 2023

5. Global Active Pharmaceutical Ingredient Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. Value
  - 5.1.1.2. Volume
- 5.1.2. By Synthesis
  - 5.1.2.1. Biotech
  - 5.1.2.1.1. Monoclonal Antibodies
  - 5.1.2.1.2. Hormones
  - 5.1.2.1.3. Cytokines
  - 5.1.2.1.4. Recombinant Proteins
  - 5.1.2.1.5. Therapeutic Enzymes
  - 5.1.2.1.6. Vaccines
  - 5.1.2.1.7. Blood Factors
  - 5.1.2.2. Synthetic
- 5.1.3. By Potency
  - 5.1.3.1. Traditional API
  - 5.1.3.2. HPAPI
- 5.1.4. By Manufacturer
  - 5.1.4.1. Captive APIs
  - 5.1.4.2. Merchant APIs
- 5.1.5. By Type
  - 5.1.5.1. Generic APIs
  - 5.1.5.2. Innovative APIs
- 5.1.6. By Drugs
  - 5.1.6.1. Prescription Drugs
  - 5.1.6.2. Over-the-counter Drugs
- 5.1.7. By Usage
  - 5.1.7.1. Clinical
  - 5.1.7.2. Research
- 5.1.8. By Application
  - 5.1.8.1. Cardiovascular Diseases
  - 5.1.8.2. Oncology
  - 5.1.8.3. CNS and Neurology
  - 5.1.8.4. Orthopedic
  - 5.1.8.5. Endocrinology
  - 5.1.8.6. Pulmonology
  - 5.1.8.7. Gastroenterology
  - 5.1.8.8. Nephrology
  - 5.1.8.9. Ophthalmology
  - 5.1.8.10. Communicable Diseases
  - 5.1.8.11. Diabetes
  - 5.1.8.12. Pain Management
  - 5.1.8.13. Others
- 5.1.9. United States*
  - 5.1.9.1. Market Size & Forecast
  - 5.1.9.1.1. Value
  - 5.1.9.1.2. Volume
  - 5.1.9.2. By Synthesis
  - 5.1.9.2.1. Biotech
  - 5.1.9.2.1.1. Monoclonal Antibodies
  - 5.1.9.2.1.2. Hormones
  - 5.1.9.2.1.3. Cytokines
  - 5.1.9.2.1.4. Recombinant Proteins
  - 5.1.9.2.1.5. Therapeutic Enzymes
  - 5.1.9.2.1.6. Vaccines
  - 5.1.9.2.1.7. Blood Factors
  - 5.1.9.2.2. Synthetic
  - 5.1.9.3. By Potency
  - 5.1.9.3.1. Traditional API
  - 5.1.9.3.2. HPAPI
  - 5.1.9.4. By Manufacturer
  - 5.1.9.4.1. Captive APIs
  - 5.1.9.4.2. Merchant APIs
  - 5.1.9.5. By Type
  - 5.1.9.5.1. Generic APIs
  - 5.1.9.5.2. Innovative APIs
  - 5.1.9.6. By Drugs
  - 5.1.9.6.1. Prescription Drugs
  - 5.1.9.6.2. Over-the-counter Drugs
  - 5.1.9.7. By Usage
  - 5.1.9.7.1. Clinical
  - 5.1.9.7.2. Research
  - 5.1.9.8. By Application
  - 5.1.9.8.1. Cardiovascular Diseases
  - 5.1.9.8.2. Oncology
  - 5.1.9.8.3. CNS and Neurology
  - 5.1.9.8.4. Orthopedic
  - 5.1.9.8.5. Endocrinology
  - 5.1.9.8.6. Pulmonology
  - 5.1.9.8.7. Gastroenterology
  - 5.1.9.8.8. Nephrology
  - 5.1.9.8.9. Ophthalmology
  - 5.1.9.8.10. Communicable Diseases
  - 5.1.9.8.11. Diabetes
  - 5.1.9.8.12. Pain Management
  - 5.1.9.8.13. Others
- 5.1.10. Canada
- 5.1.11. Mexico

All segments will be provided for all regions and countries covered:

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia-Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. Synthesis
6.2. Potency
6.3. Manufacturer
6.4. Type
6.5. Drug
6.6. Usage
6.7. Application
6.8. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Pfizer, Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Abbvie, Inc.
13.3. Novartis AG
13.4. Sanofi S.A.
13.5. F. Hoffmann-La Roche AG
13.6. Bristol-Myers Squibb Company
13.7. Merck & Co., Inc.
13.8. GlaxoSmithKline plc.
13.9. AstraZeneca plc
13.10. Eli Lilly International Corp.
13.11. Teva Pharmaceutical Industries Ltd.
13.12. Boehringer Ingelheim International GmbH
13.13. Johnson & Johnson Services, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

医薬品原薬の世界市場：合成別、力価別、メーカー別、タイプ別、薬剤別、用途別、地域別、機会、予測、2017年～2031年

Active Pharmaceutical Ingredient Market Assessment, By Synthesis, By Potency, By Manufacturer, By Type, By Drug, By Usage, By Application, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の医薬品原薬市場の見通し、2017年～2031年

第5章 世界の医薬品原薬市場の見通し、地域別、2017年～2031年

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 お問合せと免責事項

List of Tables

List of Figures

Increasing Global Demand for Pharmaceuticals

Technological Progress is Propelling the Market Forward

Government Initiatives

High Demand for HPAPIs

Growing Demand for Therapeutic Enzymes

Future Market Scenario

Key Players Landscape and Outlook

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Active Pharmaceutical Ingredient Market Outlook, 2017-2031F

5. Global Active Pharmaceutical Ingredient Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の医薬品原薬市場の見通し、2017年～2031年

第5章世界の医薬品原薬市場の見通し、地域別、2017年～2031年

第6章市場マッピング、2023年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章お問合せと免責事項